Search Results for "rapid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for rapid. Results 101 to 110 of 543 total matches.
Treatment of Hypothermia
The Medical Letter on Drugs and Therapeutics • Dec 23, 1994 (Issue 938)
° to 106° F (32.2° to 41.1° C) raises core temperature rapidly and can be
used to treat short-term ...
This winter physicians in many area may see patients suffering from hypothermia. Old age, lack of adequate housing, drug overdose and alcohol ingestion are often prediposing factors, but hypothermia also occurs in healthy young people after prolonged exposure to cold due to incapacitating trauma or cold water immersion. Hypothermia associated with exhaustionduring outdoor sports activities can occur even at relatively mild temperatures.
Trovafloxacin
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998 (Issue 1022)
, with or without food, is rapidly absorbed from the
gastrointestinal tract, reaching peak levels in serum in one ...
Trovafloxacin (Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial and community-acquired pneumonia, acute ecerbations of chronic bronchitis, acute sinusitis, complicate intra-abdominal and pelvic infections, diabetic foot infection, uncomplicated urinary tract infection, prostatitis, cervicitis and uncomplicated gonorrhea.
Argatroban For Treatment of Heparin-Induced Thrombocytopenia
The Medical Letter on Drugs and Therapeutics • Feb 05, 2001 (Issue 1097)
activate platelets and damage vascular endothelium, resulting in rapid platelet destruction ...
Argatroban, a small-molecule synthetic derivative of L-arginine, is a direct thrombin inhibitor approved by the FDA for use as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT).
Spritam - A New Formulation of Levetiracetam for Epilepsy
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
for Epilepsy
The FDA has approved a rapidly disintegrating tablet
formulation of the antiepileptic drug ...
The FDA has approved a rapidly disintegrating tablet
formulation of the antiepileptic drug levetiracetam
(Spritam – Aprecia) for adjunctive treatment of partialonset,
myoclonic, and primary generalized tonicclonic
seizures. Oral and intravenous formulations
of levetiracetam (Keppra, and generics) have been
available for years. Although approved by the FDA only
as adjunctive therapy, levetiracetam is commonly used
as monotherapy for partial-onset and generalized
seizures and may also be effective in treating absence
seizures and seizures of Lennox-Gastaut syndrome.
An Oral Cholera Vaccine for Travelers (Vaxchora)
The Medical Letter on Drugs and Therapeutics • Aug 29, 2016 (Issue 1502)
or (less commonly) O139
causes diarrhea that can be severe and can rapidly
Table 1. Recommendations ...
The FDA has approved Vaxchora (PaxVax), a single-dose,
oral, live-attenuated cholera vaccine, to protect
against disease caused by Vibrio cholerae serogroup
O1 in adults 18-64 years old traveling to cholera-affected
areas. Vaxchora is the only cholera vaccine
available in the US. A whole-cell killed injectable
vaccine was previously approved, but is no longer
available in the US.
Fosfomycin for Urinary Tract Infections
The Medical Letter on Drugs and Therapeutics • Jul 18, 1997 (Issue 1005)
to fosfomycin emerges rapidly, but cross-resistance with other antimicrobials has been uncommon (DS Reeves, J ...
Fosfomycin, a broad-spectrum antibiotic used parenterally in Europe for many years, has been approved by the US Food and Drug Administration (FDA) as fosfomycin tromethamine (Monurol - Forest) for single-dose oral treatment of uncomplicated urinary tract infections in women.
Continuous Glucose Monitoring
The Medical Letter on Drugs and Therapeutics • May 02, 2011 (Issue 1363)
also
include alarms for hypoglycemia, hyperglycemia, or a
rapid rise or fall in blood sugar.
All CGM ...
A variety of continuous glucose monitoring (CGM)
devices have been used in an effort to reduce the hypoglycemia
and wide glucose excursions that complicate
insulin treatment of diabetes. Since the last Medical
Letter issue reviewing such devices, some new devices
and some new data on old devices have become available.
The devices currently marketed in the US for personal
use are listed in Table 1.
Certolizumab Pegol (Cimzia) and Ustekinumab (Stelara) for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • Feb 03, 2014 (Issue 1435)
tolerate a TNF
inhibitor.6
CLINICAL STUDIES — A randomized, double-blind,
24-week trial (RAPID-PsA ...
Certolizumab pegol (Cimzia – UCB), a tumor necrosis
factor (TNF) inhibitor previously approved for treatment
of Crohn's disease and rheumatoid arthritis,
and ustekinumab (Stelara – Janssen), a human interleukin-12 and -23 antagonist previously approved for
treatment of moderate-to-severe plaque psoriasis,
have now been approved by the FDA for treatment of
active psoriatic arthritis.
Brexanolone (Zulresso) for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
on their efficacy are limited. Electroconvulsive
therapy is rapid-acting and has been reported to be
effective ...
The FDA has approved the GABAA receptor modulator
brexanolone (Zulresso – Sage Therapeutics) for
IV treatment of postpartum depression (PPD).
Brexanolone is the first drug to be approved by the FDA
for this indication.
In Brief: Budeprion XL 300 Has Been Withdrawn
The Medical Letter on Drugs and Therapeutics • Oct 29, 2012 (Issue 1402)
XL 300 mg releases bupropion more rapidly than
Wellbutrin XL 300 mg, the original brand name product ...
The FDA has asked Impax Laboratories/Teva Pharmaceuticals to stop production and distribution of Budeprion XL 300 mg, a generic extended-release formulation of the antidepressant bupropion (Wellbutrin XL), because it has found that Budeprion XL 300 mg releases bupropion more rapidly than Wellbutrin XL 300 mg, the original brand name product. Patients switched from the brand name to the generic formulation have complained for years that the generic was less effective and caused more side effects than the original formulation. In 2007, ConsumerLab.com, an independent laboratory, conducted...